SREN:SIXSwiss Re AG Analysis
Data as of 2026-05-16 - not real-time
CHF 121.45
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Swiss Re is trading at CHF 121.45, comfortably above its near‑term support of CHF 118.95 but well below all major moving averages – the 20‑day SMA (CHF 126.63), 50‑day SMA (CHF 128.76) and 200‑day SMA (CHF 136.49) – signaling a short‑term bearish bias. Technical indicators reinforce this view: the RSI sits at 38, the MACD line remains negative and diverges from its signal line, and the MACD histogram is still in the red, while volume has been trending upward, suggesting that any bounce may be met with fresh selling pressure. Fundamentally, the stock appears attractive: a trailing P/E of 9.99 is well below the industry average of 16.48, the dividend yield is a robust 5.15% with a payout ratio under 50%, and the upside/downside potential is modestly positive at roughly 5.5%.
The risk profile is mixed. Volatility over the past 30 days is elevated at 23%, and the maximum drawdown of over 22% reflects recent downside pressure, yet the beta is exceptionally low (≈0.15), indicating limited sensitivity to broader market swings. The reinsurance sector carries medium regulatory and sector risk, while Swiss geographic and currency exposure remain low, and liquidity is supported by increasing trading volumes.
Given the undervalued valuation relative to peers, solid dividend sustainability, and a modest upside target near CHF 128‑130, the stock is positioned for a potential rebound over the medium to long term, provided earnings stability and capital adequacy remain intact.
The risk profile is mixed. Volatility over the past 30 days is elevated at 23%, and the maximum drawdown of over 22% reflects recent downside pressure, yet the beta is exceptionally low (≈0.15), indicating limited sensitivity to broader market swings. The reinsurance sector carries medium regulatory and sector risk, while Swiss geographic and currency exposure remain low, and liquidity is supported by increasing trading volumes.
Given the undervalued valuation relative to peers, solid dividend sustainability, and a modest upside target near CHF 128‑130, the stock is positioned for a potential rebound over the medium to long term, provided earnings stability and capital adequacy remain intact.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below all major SMAs indicating bearish momentum
- Support level provides a floor but limited upside
- High dividend yield offers downside protection
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervaluation relative to industry P/E
- Attractive dividend yield with sustainable payout
- Target price upside of ~5% aligns with valuation metrics
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong ROE and stable cash generation in a defensive sector
- Low beta and resilient Swiss franc currency environment
- Consistent dividend policy supports total return
Key Metrics & Analysis
Financial Health
Revenue Growth-2.00%
Profit Margin11.74%
P/E Ratio10.0
ROE19.46%
ROA3.20%
Debt/Equity30.53
P/B Ratio1.8
Industry P/E16.5
Technical Analysis
TrendBearish
RSI38.3
SupportCHF 118.95
ResistanceCHF 133.95
MA 20CHF 126.63
MA 50CHF 128.76
MA 200CHF 136.49
MACDBearish
VolumeIncreasing
Fear & Greed Index88.52
Valuation
Target PriceCHF 128.20
Upside/Downside5.56%
GradeUndervalued
TypeValue
Dividend Yield5.15%
Risk Assessment
Beta0.15
Volatility23.43%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.